CPT code 53850 represents microwave thermotherapy for benign prostatic hyperplasia (BPH), a minimally invasive thermal ablation procedure that applies microwave energy to reduce enlarged prostatic tissue and relieve urethral obstruction. The code matters nationally as BPH is a common condition among aging men and thermal therapies are an alternative to pharmacologic management and traditional surgery, affecting utilization patterns, facility practice, and payer coverage decisions.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers can expect an overview of clinical context, typical sites of service, and common coding and billing considerations for CPT code 53850. The publication provides benchmarks for utilization and coverage trends, summarizes relevant policy updates that affect reimbursement pathways, and outlines clinical indications and limitations relevant to billing and prior authorization workflows.

This summary is intended for a national audience of coding managers, clinicians, and payer policy analysts who need concise information on the code's clinical purpose, service delivery context, and payer coverage implications. Data not provided in the input is noted where applicable.